Maruyama vaccine

Maruyama vaccine

Alternative oncology
An immune stimulant derived from the supernatant from a culture of tuberculosis (Aoyama B strain of Mycobacterium tuberculosis), which is administered as one of two different vaccines, Z-100 and the concentrated form, SSM. It may ameliorate the adverse effects of radiotherapy in cancer patients; some believe it reduces the incidence of breast, lung and colon cancer.

An estimated 50,000 Japanese receive the vaccine each year; it is not approved by the Japanese Ministry of Health, but the cost is covered by insurance companies given with conventional chemotherapy in cancer patients.